BIOATLA
BioAtla develops safer, more effective drugs for cancer using a proprietary next-generation antibody discovery and evolution platform. BioAtla is a San Diego biotech company that develops novel monoclonal antibody and cell-based therapeutics using our proprietary Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!) platforms. These and other proprietary technologies (protected by more than 150 issued patents and patent applications) allow them to develo... p novel biologics (CABs) that are better drugs in multiple ways including more selective targeting of cancer tissue and improved manufacturability. Improved selectivity for the tumor microenvironment, even when the target is also found in normal tissue, not only improves safety but also expands the universe of potential drug targets, enabling the treatment of previously untreatable cancers.
BIOATLA
Industry:
Biotechnology Health Care Medical
Founded:
2007-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.bioatla.com
Total Employee:
51+
Status:
Active
Contact:
1(858) 558-0708
Email Addresses:
[email protected]
Total Funding:
261.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Domain Not Resolving
Similar Organizations
BionPharma
BionPharma develops and commercializes affordable quality generics and builds strong and effective partnerships.
Pathway Genomics
Pathway Genomics is a CAP accredited global clinical lab offering genetic tests for cancer risk, drug responses, and other conditions.
Vital Therapies
Vital Therapies is a biotech company focused on developing a cell-based therapy targeting the treatment of acute liver failure.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Post-IPO Equity - BioAtla
Pappas Capital
Pappas Capital investment in Post-IPO Equity - BioAtla
Sphera Global Healthcare Fund
Sphera Global Healthcare Fund investment in Post-IPO Equity - BioAtla
Deerfield
Deerfield investment in Post-IPO Equity - BioAtla
Cormorant Asset Management
Cormorant Asset Management investment in Post-IPO Equity - BioAtla
Great Point Partners
Great Point Partners investment in Post-IPO Equity - BioAtla
Ikarian Capital
Ikarian Capital investment in Post-IPO Equity - BioAtla
Hudson Bay Capital Management
Hudson Bay Capital Management investment in Post-IPO Equity - BioAtla
Soleus Capital
Soleus Capital investment in Post-IPO Equity - BioAtla
Monashee Investment Management
Monashee Investment Management investment in Post-IPO Equity - BioAtla
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2017-02-16 | Exuma Biotech | BioAtla investment in Series A - Exuma Biotech | 37 M USD |
Official Site Inspections
http://www.bioatla.com Semrush global rank: 4.17 M Semrush visits lastest month: 2.85 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "BioAtla"
About Us - BioAtla
About Us Profile BioAtla© develops novel therapies with improved therapeutic index that have the potential to revolutionize cancer treatment. BioAtla© is a San Diego biotech company that …See details»
BioAtla - Crunchbase Company Profile & Funding
BioAtla develops safer, more effective drugs for cancer using a proprietary next-generation antibody discovery and evolution platform. BioAtla is a San Diego biotech company that …See details»
BioAtla, Inc. - LinkedIn
BioAtla, Inc. | 5,597 followers on LinkedIn. BioAtla is a protein therapeutic company that uses discovery and evolution to develop safer and more potent drugs for the treatment of cancer. …See details»
BioAtla - Leadership Team - The Org
The Leadership Team at BioAtla is responsible for setting the strategic direction and fostering a collaborative culture to drive the development of innovative cancer therapies. Comprising key …See details»
BioAtla Reports Fourth Quarter and Full Year 2024 Financial …
SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active …See details»
BioAtla - The Org
BioAtla develops safer, more effective drugs for cancer using a proprietary next-generation antibody discovery and evolution platform. Industries. Biotechnology, Health Care. …See details»
BioAtla - Contacts, Employees, Board Members, Advisors & Alumni
BioAtla develops safer, more effective drugs for cancer using a proprietary next-generation antibody discovery and evolution platform. ... Experience the new Crunchbase, powered by AI …See details»
Working At BioAtla: Company Overview and Culture - Zippia
Mar 14, 2024 BioAtla is a small education organization based in San Diego, CA with only 36 employees and an annual revenue of $250,000. BioAtla's Mission Statement. BioAtla© …See details»
BioAtla Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 BioAtla is a biopharmaceutical company that develops drugs for cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate …See details»
Bioatla - AnnualReports.com
BioAtla is a protein therapeutic company that uses discovery and evolution to develop safer and more potent drugs for the treatment of cancer. The culmination of their discovery and evolution …See details»
BioAtla Announces Change in Executive Leadership
Feb 27, 2023 BioAtla has extensive and worldwide patent coverage for its CAB technology and products with 704 patents (430 issued, 5 allowed, and 269 pending). Broad patent coverage in …See details»
Events and Presentations - BioAtla, Inc
BioAtla ® is a leading San Diego-based biopharmaceutical company developing safer and more effective drugs for cancer. Its Conditionally Active Biologics ™ (CAB) platform exploits the …See details»
BioAtla to Participate in the Citizens Life Sciences Conference
4 hours ago SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally …See details»
BioAtla | CipherBio
Explore BioAtla's investment information, scientific platforms, therapeutic approaches, indications and more here!See details»
BioAtla Announces Upcoming Poster Presentation at the 2025
Apr 23, 2025 BioAtla’s first dual CAB bispecific T-cell engager antibody, BA3182, is currently in Phase 1 development. BA3182 targets EpCAM, which is highly and frequently expressed on …See details»
BioAtla announces restructuring, to cut over 30% of workforce
Mar 27, 2025 Cash and cash equivalents as of December 31, 2024 were $49M , compared to $111.5M as of December 31, 2023. We expect that cost reductions to be...See details»
BIOATLA APPOINTS EDWARD L. WILLIAMS TO BOARD OF …
SAN DIEGO, Dec. 21, 2021 /PRNewswire/ -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody …See details»
BioAtla lays off 30% of staff, hunts for partners for ADC
Mar 28, 2025 BioAtla is laying off 30% of staff as the biotech searches for partners for some of its conditionally active biologic (CAB) antibodies while eking out its cash to cover a slew of …See details»
Technology - BioAtla
BioAtla ® is a leading San Diego-based biopharmaceutical company developing safer and more effective drugs for cancer. Its Conditionally Active Biologics ™ (CAB) platform exploits the …See details»
Breakthrough antibody technology to broaden therapeutic
BioAtla at a Glance Technology • Proprietary CAB technology creates antibodies that conditionally and reversibly bind to tumors, but not normal cells, enabling increased antibody potency and …See details»